Mesoblast MESO 深 滬
等待開盤 12-23 09:30:00 美东时间
19.42
-0.060
-0.31%
華盛通- 最 高19.52
- 今 開19.43
- 成交量 14.96万股
- 最 低 19.145
- 昨 收 19.48
- 總市值 24.86亿
- 52周最高 22.00
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 9.61
- 委 比 -96.89%
- 總股本 1.28亿
- 歷史最高 58.4372
- 量 比 0.46
- 振 幅 1.93%
- 歷史最低 1.9406
- 每 手 1
- 風險率 2.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
12-17 00:53
Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD Treatment
Mesoblast Limited ( ($AU:MSB) ) has provided an update. An independent study pr...
12-12 08:37
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
Mesoblast Limited announced that an independent, peer-reviewed comparative analysis of remestemcel-L and ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD) showed remestemcel-L had superior outcomes in complete and overall remission. The analysis involved 2,732 patients across 11 studies, with remestemcel-L demonstrating better efficacy and differences in adverse events, though both therapies had favorable safe...
12-11 23:22
State Street Ceases Substantial Holding in Mesoblast
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
12-10 17:27
Mesoblast Participation at Piper Sandler Conference
Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, announced its participation in the Piper Sandler 37th Annual Healthcare Conference in New York. Silviu Itescu, the company’s CEO, will join a fireside chat on December 4, 2025. Mesoblast specializes in developing off-the-shelf cellular therapies to treat severe inflammatory conditions. Its FDA-approved Ryoncil® is used for steroid-refractory acute graft...
12-03 23:10
Mesoblast Achieves FDA Approval for Ryoncil®
An update from Mesoblast ( ($MESO) ) is now available. On November 25, 2025, Me...
11-25 22:58
Jefferies Upgrades Mesoblast to Buy
Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.
11-25 21:39
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
<p>Mesoblast Limited has announced a pivotal Phase 3 trial collaboration with the U.S. National Institutes of Health-funded BMT CTN to evaluate Ryoncil® for adults with severe acute graft versus host disease (aGvHD) that fails corticosteroids. The trial aims to extend Ryoncil®'s life-saving potential to adults, following its FDA approval for children. Mesoblast's Expanded Access program showed 76% survival at Day 100 in adults failing ruxolitinib...
11-20 23:32
Mesoblast Appoints New CFO Amidst Commercial Transition
Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast Limited has a...
11-17 09:38
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
Mesoblast Limited announced the appointment of James M. O'Brien as its US-based Chief Financial Officer. With extensive experience in financial management and planning across life sciences, biotechnology, and pharmaceutical industries, Jim will oversee Mesoblast's transition to a mature commercial organization. His expertise will support the commercialization of Ryoncil® and future label expansion. Mesoblast is a global leader in allogeneic cellu...
11-17 06:52
